Thiazolidinediones and edema: Recent advances in the pathogenesis of Thiazolidinediones-induced renal sodium retention

PPAR Research

Volumn 2015, Issue , 2015, Pages

  Horita, Shoko ^a   Nakamura, Motonobu ^a   Satoh, Nobuhiko ^a   Suzuki, Masashi ^a   Seki, George ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AQUAPORIN; BICARBONATE SODIUM COTRANSPORTER; EPITHELIAL SODIUM CHANNEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SODIUM POTASSIUM CHLORIDE COTRANSPORTER 2; SODIUM PROTON EXCHANGE PROTEIN;

BLADDER CANCER; BLOOD VESSEL PERMEABILITY; CONGESTIVE HEART FAILURE; EDEMA; FRACTURE; GLUCOSE METABOLISM; HENLE LOOP; HUMAN; KIDNEY; KIDNEY DYSFUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE; NONHUMAN; PATHOGENESIS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SODIUM ABSORPTION; SODIUM RETENTION; UPREGULATION; WATER RETENTION;

EID: 84930675015     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2015/646423     Document Type: Review

References (84)

1. R. M. Evans, G. D. Barish, and Y. Wang, "PPARs and the complex journey to obesity", Nature Medicine, vol. 10, no. 4, pp. 355-361, 2004.
2. R. Eldor, R. A. DeFronzo, and M. Abdul-Ghani, "In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion", Diabetes Care, vol. 36, no. 2, pp. S162-S174, 2013.
3. M. Ahmadian, J. M. Suh, N. Hah et al., "PPARγ signaling and metabolism: the good, the bad and the future", Nature Medicine, vol. 19, no. 5, pp. 557-566, 2013.
4. C. Helsen and F. Claessens, "Looking at nuclear receptors from a new angle", Molecular and Cellular Endocrinology, vol. 382, no. 1, pp. 97-106, 2014.
5. A. Elbrecht, Y. Chen, C. A. Cullinan et al., "Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2", Biochemical and Biophysical Research Communications, vol. 224, no. 2, pp. 431-437, 1996.
6. M. E. Greene, B. Blumberg, O. W. McBride et al., "isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping", Gene Expression, vol. 4, no. 4-5, pp. 281-299, 1995.
7. A. J. Vidal-Puig, R. V. Considine, M. Jimenez-Liñan et al., "Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids", The Journal of Clinical Investigation, vol. 99, no. 10, pp. 2416-2422, 1997.
8. P. Tontonoz, R. A. Graves, A. I. Budavari et al., "Adipocytespecific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARγ and RXRα", Nucleic Acids Research, vol. 22, no. 25, pp. 5628-5634, 1994.
9. G. Medina-Gomez, S. L. Gray, L. Yetukuri et al., "PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism", PLoS Genetics, vol. 3, no. 4, p. e64, 2007.
10. P. Tontonoz and B. M. Spiegelman, "Fat and beyond: the diverse biology of PPARγ", Annual Review of Biochemistry, vol. 77, pp. 289-312, 2008.
11. N. Kubota, Y. Terauchi, H. Miki et al., "PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance", Molecular Cell, vol. 4, no. 4, pp. 597-609, 1999.
12. Y. Endo, M. Suzuki, H. Yamada et al., "Tiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling", Cell Metabolism, vol. 13, no. 5, pp. 550-561, 2011.
13. J. Song, M. A. Knepper, X. Hu, J. G. Verbalis, and C. A. Ecelbarger, "Rosiglitazone activates renal sodium- and waterreabsorptive pathways and lowers blood pressure in normal rats", The Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 2, pp. 426-433, 2004.
14. Y. Guan, C. Hao, D. R. Cha et al., "Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption", Nature Medicine, vol. 11, no. 8, pp. 861-866, 2005.
15. H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang, "Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention", Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9406-9411, 2005.
16. V. Vallon, E. Hummler, T. Rieg et al., "Thiazolidinedioneinduced fluid retention is independent of collecting duct αENaC activity", Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 721-729, 2009.
17. E. Borsting, V. P.-C. Cheng, C. K. Glass, V. Vallon, and R. Cunard, "Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney", The American Journal of Physiology-Renal Physiology, vol. 302, no. 5, pp. F540-F551, 2012.
18. C. Nofziger, L. Chen, M. A. Shane, C. D. Smith, K. K. Brown, and B. L. Blazer-Yost, "PPARγ agonists do not directly enhance basal or insulin-stimulated Na+ transport via the epithelial Na+ channel", Pflugers Archiv, vol. 451, no. 3, pp. 445-453, 2005.
19. Y. Iwashima, M. Eto, S. Horiuchi, and H. Sano, "Advanced glycation end product-induced peroxisome proliferator-activated receptor γ gene expression in the cultured mesangial cells", Biochemical and Biophysical Research Communications, vol. 264, no. 2, pp. 441-448, 1999.
20. T. Asano, M. Wakisaka, M. Yoshinari et al., "Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation", Biochimica et Biophysica Acta, vol. 1497, no. 1, pp. 148-154, 2000.
21. H. Mudaliar, C. Pollock, M. G. Komala, S. Chadban, H. Wu, and U. Panchapakesan, "The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules", American Journal of Physiology-Renal Physiology, vol. 305, no. 2, pp. F143-F154, 2013.
22. Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer, "Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans", American Journal of Physiology-Renal Physiology, vol. 273, no. 6, pp. F1013-F1022, 1997.
23. J. Yang, Y. Zhou, and Y. Guan, "PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases", Current Opinion in Nephrology and Hypertension, vol. 21, no. 1, pp. 97-105, 2012.
24. T. Kanjanabuch, L.-J. Ma, J. Chen et al., "PPAR-γ agonist protects podocytes from injury", Kidney International, vol. 71, no. 12, pp. 1232-1239, 2007.
25. J. M. Rutkowski, Z. V. Wang, A. S. D. Park et al., "Adiponectin promotes functional recovery After podocyte ablation", Journal of the American Society of Nephrology, vol. 24, no. 2, pp. 268-282, 2013.
26. G. J. Ko, Y. S. Kang, S. Y. Han et al., "Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats", Nephrology Dialysis Transplantation, vol. 23, no. 9, pp. 2750-2760, 2008.
27. B. Guo, D. Koya, M. Isono, T. Sugimoto, A. Kashiwagi, and M. Haneda, "Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β1-induced fibronectin expression in glomerular mesangial cells", Diabetes, vol. 53, no. 1, pp. 200-208, 2004.
28. T. Fujita, Y. Sugiyama, S. Taketomi et al., "Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2, 4-dione (ADD-3878, U-63, 287, Ciglitazone), a new antidiabetic agent", Diabetes, vol. 32, no. 9, pp. 804-810, 1983.
29. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation", Cell, vol. 83, no. 5, pp. 813-819, 1995.
30. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferatoractivated receptor γ (PPARγ)", Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953-12956, 1995.
31. Y. Miyazaki and R. A. DeFronzo, "Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients", Diabetes, Obesity and Metabolism, vol. 10, no. 12, pp. 1204-1211, 2008.
32. Y. Miyazaki, A. Mahankali, M. Matsuda et al., "Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone", Diabetes Care, vol. 24, no. 4, pp. 710-719, 2001.
33. A. Gastaldelli, Y. Miyazaki, M. Pettiti et al., "The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes", Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3, pp. 806-812, 2006.
34. R. A. Defronzo, "From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus", Diabetes, vol. 58, no. 4, pp. 773-795, 2009.
35. A. Gastaldelli, Y. Miyazaki, A. Mahankali et al., "The effect of pioglitazone on the liver: role of adiponectin", Diabetes Care, vol. 29, no. 10, pp. 2275-2281, 2006.
36. J. H. Choi, A. S. Banks, J. L. Estall et al., "Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ 3 by Cdk5", Nature, vol. 466, no. 7305, pp. 451-456, 2010.
37. A. S. Banks, F. E. McAllister, J. P. Camporez et al., "An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ", Nature, vol. 517, no. 7534, pp. 391-395, 2014.
38. K. J. McCarthy, R. E. Routh, W. Shaw, K. Walsh, T. C. Welbourne, and J. H. Johnson, "Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion", Kidney International, vol. 58, no. 6, pp. 2341-2350, 2000.
39. T. Yoshimoto, M. Naruse, M. Nishikawa et al., "Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats", The American Journal of Physiology-Endocrinology and Metabolism, vol. 272, no. 6, pp. E989-E996, 1997.
40. J. Weissgarten, S. Berman, S. Efrati, M. Rapoport, Z. Averbukh, and L. Feldman, "Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats", Nephrology Dialysis Transplantation, vol. 21, no. 5, pp. 1198-1204, 2006.
41. C. Weigert, K. Brodbeck, A. Bierhaus, H. U. Häring, and E. D. Schleicher, "c-Fos-driven transcriptional activation of transforming growth factor beta-1: inhibition of high glucoseinduced promoter activity by thiazolidinediones", Biochemical and Biophysical Research Communications, vol. 304, no. 2, pp. 301-307, 2003.
42. S. Yoshioka, H. Nishino, T. Shiraki et al., "Antihypertensive effects of CS-045 treatment in obese Zucker rats", Metabolism: Clinical and Experimental, vol. 42, no. 1, pp. 75-80, 1993.
43. P. A. Sarafidis and G. L. Bakris, "Protection of the kidney by thiazolidinediones: an assessment from bench to bedside", Kidney International, vol. 70, no. 7, pp. 1223-1233, 2006.
44. T. Nakamura, C. Ushiyama, N. Shimada, K. Hayashi, I. Ebihara, and H. Koide, "Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients", Journal of Diabetes and its Complications, vol. 14, no. 5, pp. 250-254, 2000.
45. T. Nakamura, C. Ushiyama, S. Osada, M. Hara, N. Shimada, and H. Koide, "Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria", Metabolism: Clinical and Experimental, vol. 50, no. 10, pp. 1193-1196, 2001.
46. R. A. DeFronzo, D. Tripathy, D. C. Schwenke et al., "Pioglitazone for diabetes prevention in impaired glucose tolerance", The New England Journal of Medicine, vol. 364, no. 12, pp. 1104-1115, 2011.
47. T. Yanagawa, A. Araki, K. Sasamoto, S. Shirabe, and T. Yamanouchi, "Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes", Metabolism, vol. 53, no. 3, pp. 353-357, 2004.
48. K. Aljabri, S. E. Kozak, and D. M. Thompson, "Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial", American Journal of Medicine, vol. 116, no. 4, pp. 230-235, 2004.
49. B. Cariou, B. Charbonnel, and B. Staels, "Thiazolidinediones and PPARγ agonists: time for a reassessment", Trends in Endocrinology and Metabolism, vol. 23, no. 5, pp. 205-215, 2012.
50. J. V. Huang, C. R. Greyson, and G. G. Schwartz, "PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty", Journal of Lipid Research, vol. 53, no. 9, pp. 1738-1754, 2012.
51. A. Benbow, M. Stewart, and G. Yeoman, "Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure", British Medical Journal, vol. 322, article 236, 2001.
52. E. Erdmann and R. G. Wilcox, "Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure", European Heart Journal, vol. 29, no. 1, pp. 12-20, 2008.
53. K. B. Sotiropoulos, A. Clermont, Y. Yasuda et al., "Adiposespecific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARγ agonist's effects on edema and weight gain", The FASEB Journal, vol. 20, no. 8, pp. 1203-1205, 2006.
54. D. Kotake and N. Hirasawa, "Activation of a retinoic acid receptor pathway by thiazolidinediones induces production of vascular endothelial growth factor/vascular permeability factor in OP9 adipocytes", European Journal of Pharmacology, vol. 707, no. 1-3, pp. 95-103, 2013.
55. A. D. Dede, S. Tournis, I. Dontas, and G. Trovas, "Type 2 diabetes mellitus and fracture risk", Metabolism, vol. 63, no. 12, pp. 1480-1490, 2014.
56. A. Grey, M. Bolland, S. Fenwick et al., "The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial", European Journal of Endocrinology, vol. 170, no. 2, pp. 255-262, 2014.
57. J. P. Bilezikian, R. G. Josse, R. Eastell et al., "Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus", Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 4, pp. 1519-1528, 2013.
58. M. Monami, I. Dicembrini, and E. Mannucci, "Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials", Acta Diabetologica, vol. 51, no. 1, pp. 91-101, 2014.
59. J. A. Dormandy, B. Charbonnel, D. J. A. Eckland et al., "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial", The Lancet, vol. 366, no. 9493, pp. 1279-1289, 2005.
60. R. W. Nesto, D. Bell, R. O. Bonow et al., "Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association", Diabetes Care, vol. 27, no. 1, pp. 256-263, 2004.
61. P. Raskin, M. Rendell, M. C. Riddle, J. F. Dole, M. I. Freed, and J. Rosenstock, "A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes", Diabetes Care, vol. 24, no. 7, pp. 1226-1232, 2001.
62. P. A. Sarafidis, P. I. Georgianos, and A. N. Lasaridis, "PPAR-γ agonism for cardiovascular and renal protection", Cardiovascular Therapeutics, vol. 29, no. 6, pp. 377-384, 2011.
63. E. Erdmann, J. A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I. K. Moules, and A. M. Skene, "The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study", Journal of the American College of Cardiology, vol. 49, no. 17, pp. 1772-1780, 2007.
64. R. M. Lago, P. P. Singh, and R. W. Nesto, "Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials", The Lancet, vol. 370, no. 9593, pp. 1129-1136, 2007.
65. R. W. Nesto, D. Bell, R. O. Bonow et al., "Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association", Circulation, vol. 108, no. 23, pp. 2941-2948, 2003.
66. G. Hong, A. Lockhart, B. Davis et al., "PPAR gamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells", The FASEB Journal, vol. 17, no. 13, pp. 1966-1968, 2003.
67. -3 cotransport activity in rabbit proximal straight tubules", Nephron Experimental Nephrology, vol. 9, no. 3, pp. 191-197, 2001.
68. A. Zanchi, A. Chiolero, M. Maillard, J. Nussberger, H.-R. Brunner, and M. Burnier, "Effects of the peroxisomal proliferatoractivated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men", The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 3, pp. 1140-1145, 2004.
69. J. M. Gonzalez-Campoy, J. C. Romero, and F. G. Knox, "Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems", Kidney International, vol. 35, no. 3, pp. 767-777, 1989.
70. S. C. Kiley and R. L. Chevalier, "Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF", The American Journal of Physiology-Renal Physiology, vol. 293, no. 3, pp. F895-F903, 2007.
71. E. Burgermeister and R. Seger, "PPARγ and MEK interactions in cancer", PPAR Research, vol. 2008, Article ID 309469, 16 pages, 2008.
72. S. Kousteni, T. Bellido, L. I. Plotkin et al., "Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity", Cell, vol. 104, no. 5, pp. 719-730, 2001.
73. -3 transport", Journal of the American Society of Nephrology, vol. 19, no. 2, pp. 252-259, 2008.
74. D.-H. Lee, D.-B. Park, Y.-K. Lee et al., "The effects of thiazolidinedione treatment on the regulations of aquaglyceroporins and glycerol kinase in OLETF rats", Metabolism: Clinical and Experimental, vol. 54, no. 10, pp. 1282-1289, 2005.
75. L. Zhou, G. Liu, Z. Jia et al., "Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters", American Journal of Physiology-Renal Physiology, vol. 305, no. 10, pp. F1491-F1497, 2013.
76. B. Edemir, H. Pavenstädt, E. Schlatter, and T. Weide, "Mechanisms of cell polarity and aquaporin sorting in the nephron", Pflügers Archiv European Journal of Physiology, vol. 461, no. 6, pp. 607-621, 2011.
77. M. L. A. Kortenoeven and R. A. Fenton, "Renal aquaporins and water balance disorders", Biochimica et Biophysica Acta-General Subjects, vol. 1840, no. 5, pp. 1533-1549, 2014.
78. J. L. Wilson, C. A. Miranda, and M. A. Knepper, "Vasopressin and the regulation of aquaporin-2", Clinical and Experimental Nephrology, vol. 17, no. 6, pp. 751-764, 2013.
79. T. Ma, Y. Song, B. Yang et al., "Nephrogenic diabetes insipidus in mice lacking aquaporin-3 water channels", Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 8, pp. 4386-4391, 2000.
80. H. Castrop and I. M. Schiessl, "Physiology and pathophysiology of the renal Na-K-2Cl cotransporter (NKCC2)", The American Journal of Physiology: Renal Physiology, vol. 307, no. 9, pp. F991-F1002, 2014.
81. N. Markadieu and E. Delpire, "Physiology and pathophysiology of SLC12A1/2 transporters", Pflugers Archiv European Journal of Physiology, vol. 466, no. 1, pp. 91-105, 2014.
82. Y. Fu, M. Gerasimova, F. Batz et al., "PPARγ agonist-induced fluid retention depends on aENaC expression in connecting tubules", Nephron, vol. 129, no. 1, pp. 68-74, 2015.
83. H. S. Chou, K. E. Truitt, J. B. Moberly et al., "A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus", Diabetes, Obesity and Metabolism, vol. 14, no. 11, pp. 1000-1009, 2012.
84. A. M. DePaoli, L. S. Higgins, R. R. Henry, C. Mantzoros, F. L. Dunn, and INT131-007 Study Group, "Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?" Diabetes Care, vol. 37, no. 7, pp. 1918-1923, 2014.